Scorpius Biomanufacturing
Scorpius Biomanufacturing was a San Antonio-based public CDMO offering GMP mammalian, microbial, and cell therapy manufacturing services to biopharmaceutical clients, including CGMP validation for BLA submissions. The company ceased operations in early 2026 after failing to scale beyond a single named customer engagement.
- Company typePublic
- Founded2020
- HeadquartersSan Antonio, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Scorpius Biomanufacturing does
Scorpius Biomanufacturing (legally Scorpius Holdings, Inc.) was a contract development and manufacturing organization (CDMO) headquartered in San Antonio, Texas, specializing in mammalian, microbial, and cell therapy biologics. Founded in 2020 and publicly listed on NYSE American (ticker: SCPX), the company offered GMP manufacturing services, CGMP validation support, and production testing intended to enable clients' BLA submissions. Its customer base was concentrated in the biopharmaceutical vertical, with the only documented engagement being a September 2025 partnership with Tivic Health Systems for CGMP validation of the Entolimod cell line as a treatment for acute radiation syndrome.
The company's revenue model was service-based contract manufacturing for biologic and cell therapy programs, though no pricing or contract-value details were publicly disclosed. Scorpius raised $1.5 million in a March 2024 public offering of 10 million shares at $0.15 per share to fund working capital and general corporate purposes. Despite its public listing, the company was small (51–100 employees), held no documented patents, certifications, or proprietary technology platforms, and operated from a single San Antonio site. The only named executive in the data is Shari Udoff-McDonald, Vice President of Business Development. By early 2026, the company had shuttered operations and its facility was acquired by a subsidiary of a California company, effectively ending the business following a difficult year.
Scorpius Biomanufacturing firmographics
Firmographics- Name
- Scorpius Biomanufacturing
- Legal name
- Scorpius Holdings, Inc.
- Website
- https://scorpiusbiologics.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Closed
- Headcount range
- 51–100 employees
- Short description
- Scorpius Biomanufacturing was a San Antonio-based public CDMO offering GMP mammalian, microbial, and cell therapy manufacturing services to biopharmaceutical clients, including CGMP validation for BLA submissions. The company ceased operations in early 2026 after failing to scale beyond a single named customer engagement.
- Ownership category
- akta.pro rank
Scorpius Biomanufacturing industry classification
Industry- Product category
- Biologics Contract Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Cell Therapy CDMO (HLAGABAD), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where Scorpius Biomanufacturing is headquartered
LocationHeadquarters
- HQ city
- San Antonio
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Scorpius Biomanufacturing business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Scorpius Biomanufacturing product offering
Product offeringCore offering
Scorpius Biomanufacturing operated as a contract development and manufacturing organization (CDMO) providing mammalian cell culture, microbial fermentation, and cell therapy manufacturing services for biologic drug developers. The company offered CGMP production, process validation, and analytical testing services to support client BLA submissions and commercialization of biologic and cell therapy products.
Differentiator
Problem solved
Functional benefit
Products and services
- Mammalian cell culture manufacturing services Contract manufacturing of biologic drug substances using mammalian cell culture platforms for biopharmaceutical clients developing therapeutic proteins and monoclonal antibodies.
- Microbial fermentation manufacturing services Contract microbial fermentation production of biologic drug substances for biopharmaceutical clients requiring bacterial or yeast-based expression systems.
- Cell therapy manufacturing services Contract manufacturing of cell therapy products for biopharmaceutical clients developing cell-based therapeutics, supporting process development through commercial production.
- CGMP validation and BLA submission support Current Good Manufacturing Practice (CGMP) validation of cell lines, production and analytical testing of therapeutic proteins, and regulatory support services to enable client BLA submissions to the FDA.
Companies that use Scorpius Biomanufacturing
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Scorpius Biomanufacturing technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Scorpius Biomanufacturing partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Tivic Health SystemscoreTivic Health Systems partnered with Scorpius Biomanufacturing for GMP validation of its Entolimod cell line. The collaboration involved successful production and testing of Entolimod proteins, a key step toward establishing CGMP manufacturing for BLA submission to advance Entolimod's commercialization as a treatment for acute radiation syndrome.
Scale indicators2 records
Recent moves4 records
Expansion highlights2 records
Scorpius Biomanufacturing competitors and assessment
Company assessmentBroad incumbents
- WuXi Biologics: WuXi Biologics is one of the largest global CDMOs for biologics, offering end-to-end mammalian and microbial services. Comparable in service offering to Scorpius's biologics CDMO scope, though vastly larger and with a different geographic/customer base.
- Catalent: Catalent is a major CDMO spanning biologics, cell therapies, and fill-finish across multiple modalities. Comparable to Scorpius in the breadth of biologic and cell therapy services it offers to biopharma clients, but at vastly greater scale.
- Lonza Group: Lonza is the world's largest biologics CDMO with extensive mammalian, microbial, and cell & gene therapy capacity. It is the benchmark incumbent that any sub-scale CDMO like Scorpius must position against, and it defines the addressable menu of services Scorpius was attempting to offer.
- Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth is a leading CDMO for mammalian and microbial biologics with large-scale GMP capacity. It is directly comparable to Scorpius's mammalian/microbial CDMO positioning, operating at a much larger scale.
- Samsung Biologics: Samsung Biologics is a large-scale mammalian biologics CDMO serving global biopharma. Comparable to Scorpius's mammalian biologics CDMO positioning, but operating at mega-scale with very different capital and capacity economics.
Direct peers
- Vibalogics: Vibalogics is a specialized CDMO focused on virotherapy, gene therapy, and viral vector manufacturing, with cell therapy capabilities. Directly comparable to Scorpius's cell therapy and biologics CDMO positioning for advanced therapy developers.
- AGC Biologics: AGC Biologics is a mid-to-large CDMO offering mammalian, microbial, and cell/gene therapy services to biopharma. It is one of the closest direct peers to Scorpius in modality mix and customer profile, though with substantially greater capacity.
- BioVectra: BioVectra is a mid-sized CDMO offering biologics and fermentation-based (microbial) manufacturing plus fill-finish. Directly comparable to Scorpius's mammalian/microbial CDMO positioning and serves a similar small-to-mid biopharma client base.
- KBI Biologics: KBI Biologics is a mid-sized CDMO focused on mammalian and microbial biologics process development and manufacturing. Closely comparable to Scorpius in scale and customer profile for biologic CDMO services.
- Rentschler Biologics: Rentschler Biologics is a mid-sized CDMO specializing in mammalian cell culture biologics manufacturing. Closely comparable to Scorpius in modality (mammalian biologics), service menu, and customer profile, though with stronger financial backing.
Market position
Strengths2 records
Weaknesses2 records
Competitive moat2 records
Key risks6 records
Key highlights3 records
Customer concentration
Scorpius Biomanufacturing social profiles
Digital presenceScorpius Biomanufacturing financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scorpius Biomanufacturing leadership team
Management profileNumber of profiles
Profiles1 record
Scorpius Biomanufacturing funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scorpius Biomanufacturing M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scorpius Biomanufacturing
What does Scorpius Biomanufacturing do?
Scorpius Biomanufacturing operated as a contract development and manufacturing organization (CDMO) providing mammalian cell culture, microbial fermentation, and cell therapy manufacturing services for biologic drug developers. The company offered CGMP production, process validation, and analytical testing services to support client BLA submissions and commercialization of biologic and cell therapy products.
Is Scorpius Biomanufacturing a public or private company?
Scorpius Biomanufacturing is a public company. It is classified as public and is currently closed.
When was Scorpius Biomanufacturing founded?
Scorpius Biomanufacturing was founded in 2020. It employs 51 to 100 people.
Where is Scorpius Biomanufacturing based?
Scorpius Biomanufacturing is headquartered in San Antonio, United States, in the North America region.
Who are Scorpius Biomanufacturing's main competitors?
Broad incumbents on record are WuXi Biologics, Catalent, Lonza Group, Fujifilm Diosynth Biotechnologies and Samsung Biologics. Direct peers are Vibalogics, AGC Biologics, BioVectra, KBI Biologics and Rentschler Biologics.
Does Scorpius Biomanufacturing have an API?
No public API is recorded for Scorpius Biomanufacturing.
What industry is Scorpius Biomanufacturing in?
Scorpius Biomanufacturing's product category is Biologics Contract Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 8731.